(Q42865759)

8 November 2017

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients (English)

1 reference

8 November 2017

1 reference

3

1 reference

8 November 2017

7

Michael P Manns

1 reference

8 November 2017

8

Heiner Wedemeyer

1 reference

8 November 2017

Karsten Wursthorn

1

1 reference

8 November 2017

Mechthild Jung

2

1 reference

8 November 2017

Zachary D Goodman

4

1 reference

8 November 2017

Patricia Lopez

5

1 reference

8 November 2017

Weibin Bao

6

1 reference

8 November 2017

Nikolai V Naoumov

9

1 reference

8 November 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

8 November 2017

1 reference

8 November 2017

52

1 reference

8 November 2017

5

1 reference

8 November 2017

1611-1620

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

8 November 2017

1 reference

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

7 January 2021

Chronic hepatitis B: update 2009

1 reference

7 January 2021

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

7 January 2021

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

1 reference

7 January 2021

HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up

1 reference

7 January 2021

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

1 reference

7 January 2021

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

1 reference

7 January 2021

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

1 reference

7 January 2021

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.

1 reference

7 January 2021

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

1 reference

7 January 2021

Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a

1 reference

7 January 2021

Hepatitis B virus infection--natural history and clinical consequences

1 reference

7 January 2021

HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.

1 reference

7 January 2021

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

1 reference

7 January 2021

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

1 reference

7 January 2021

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

7 January 2021

Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.

1 reference

7 January 2021

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype

1 reference

7 January 2021

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

1 reference

7 January 2021

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

1 reference

7 January 2021

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia

1 reference

7 January 2021

Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens.

1 reference

7 January 2021

Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23905

1 reference

8 November 2017

1 reference